- Home
- AUTL vs AVIR Comparison
AUTL vs AVIR Comparison
Compare AUTL & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 434.5M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUTL | AVIR |
|---|---|---|
| Price | $1.70 | $4.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.6M | 307.6K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $10,120,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $2.78 |
| 52 Week High | $2.70 | $6.45 |
Technical Indicators
Market Signals| Indicator | AUTL | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 42.69 |
| Support Level | $1.27 | $3.27 |
| Resistance Level | $1.73 | $4.80 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 49.03 | 39.24 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.